“…Godfrey et al [ 71 ] developed a chitosan-based nanoparticle formulation for intranasal delivery of native ENK and showed strong antinociception without inducing tolerance or hyperactivity after repeated administrations. Similarly, dual enkephalinase inhibitors, which increase the extracellular level of ENKs were shown to produce antinociception without respiratory disturbance, constipation, analgesic tolerance, addiction, or dependence in several animal models [ 64 , 65 , 66 , 67 , 70 , 73 , 74 , 75 ].…”